Similarly, this can be applied to avoid off-target effects such as DT2216 that targets BCL-xL for degradation through the recruitment of VHL with a decreased expression in platelets subsequently resulting in reduced on-target platelet toxicity (thrombocytopenia) and an enhanced therapeutic index compared to conventional BCL-xL inhibitors (Zhang et al., 2019b; Zhang X. et al., 2020; Negi and Voisin-Chiret, 2022). The gene discussed is BCL2L1; the disease is Thrombocytopenia.